Clinical trials · Dallas–Fort Worth, TX
Advanced Cancer clinical trials in Dallas–Fort Worth
We’re tracking 153 recruiting advanced cancer studies with a site in or near Dallas–Fort Worth — including Phase 1, Phase 1/Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Dallas–Fort Worth
- NCT05873686RecruitingPhase 1
Study of NXP900 for advanced solid tumors
This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.
Irving, TexasAges 18 years+ - NCT06975293RecruitingPhase 1/Phase 2
STC-15 with toripalimab for advanced cancers and sarcomas
This trial tests a new drug called STC-15, either alone or with another drug (toripalimab), for people with certain advanced cancers or sarcomas that have progressed after prior treatment. The goal is to see if this combination or single drug can help shrink tumors or slow the disease.
Irving, TexasAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
Irving, TexasAges 18 years+ - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
Irving, TexasAges 18 years+ - NCT07454642RecruitingPhase 1
AVA6103 for advanced FAP-positive solid tumors
This trial tests a new drug called AVA6103 for certain advanced cancers that show a protein called FAP. It is for people who have already tried other treatments or cannot take them, and aims to see if the drug is safe and helps shrink tumors.
Irving, TexasAges 18 years+ - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Irving, TexasAges 18 years+ - NCT07535112RecruitingPhase 1
Testing BAY 3771249 for Advanced Colorectal Cancer With KRAS Mutation
This early-stage study tests a new drug called BAY 3771249 in people with advanced colorectal cancer that has a specific genetic change (KRAS G12D mutation). Researchers want to learn if it's safe and whether it helps shrink tumors.
Irving, TexasAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
Irving, TexasAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Irving, TexasAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Irving, TexasAges 18 years+ - NCT06823167RecruitingPhase 1
Study of IM-1021 for advanced B-cell lymphoma or solid tumors
This trial tests a new drug, IM-1021, for people with advanced B-cell lymphomas or certain solid tumors that have not responded to or have come back after standard treatments. The drug targets a protein called ROR1 on cancer cells to try to stop the cancer from growing.
Irving, TexasAges 18 years+ - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Irving, TexasAges 18 years+ - NCT06065748RecruitingPhase 3
New hormone therapy for advanced breast cancer after prior treatment
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
Irving, TexasAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
Irving, TexasAges 18 years+ - NCT06120283RecruitingPhase 1
Testing a new drug for breast cancer and other solid tumors
This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.
Irving, TexasAges 18 years+ - NCT06657222RecruitingPhase 1/Phase 2
Study of TUB-030 for advanced solid tumors
This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Irving, TexasAges 18 years+ - NCT07066657RecruitingPhase 1
Study of MRG007 for advanced solid tumors
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
Irving, TexasAges 18 years+ - NCT03424005RecruitingPhase 1/Phase 2
Testing new drug combinations for advanced breast cancer
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
Plano, TexasAges 18 years+ - NCT07291037RecruitingPhase 3
Study of datopotamab deruxtecan vs docetaxel for advanced lung cancer
This trial tests a new drug, datopotamab deruxtecan, against a standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has gotten worse after previous treatment. It is for those who do not have certain genetic changes (like EGFR, ALK, or ROS1) and whose tumors have a protein called TROP2.
Plano, TexasAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Izalontamab Brengitecan vs chemo for certain breast cancers
This trial tests a new drug called Izalontamab Brengitecan against standard chemotherapy for people with untreated advanced triple-negative or ER-low breast cancer who cannot take certain immunotherapy drugs.
Flower Mound, TexasAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Fort Worth, TexasAges 18 years+ - NCT05894239RecruitingPhase 3
Tested targeted drug for HER2-positive breast cancer with PIK3CA changes
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
Fort Worth, TexasAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Fort Worth, TexasAges 18 years+ - NCT05797831RecruitingPhase 2/Phase 3
Maintenance treatment for TP53-wildtype endometrial cancer
This trial tests navtemadlin as a maintenance (ongoing) treatment to help prevent endometrial cancer from coming back after chemotherapy works. It is mainly for people whose cancer has certain genetic features (TP53 “wildtype”) and who had a strong response to first-line taxane–platinum chemo.
Fort Worth, TexasAges 18 years+
Hear when a new Advanced Cancer trial opens near Dallas–Fort Worth, TX
We’ll email you when one opens near Dallas–Fort Worth, TX — at most once a week, no account needed, unsubscribe anytime.
Advanced Cancer trials in other cities
Where these studies are running near Dallas–Fort Worth
Institutions with a site for the recruiting advanced cancer studies listed above.
- NEXT Oncology · 13 studies
- JPS Health Network · 3 studies
- Research Site · 2 studies
- Texas Oncology - DFW · 2 studies
- Texas Oncology - Northeast Texas · 2 studies
- US Oncology Investigational Products Center (IPC) · 2 studies
- Avenzo Therapeutics Recruiting Site
- Texas Oncology
What taking part in a advanced cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced cancer studies in Texas.
Common questions
- Are there advanced cancer clinical trials near Dallas–Fort Worth?
- Yes. We're currently tracking 153 recruiting advanced cancer studies with a site near Dallas–Fort Worth, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced cancer study near Dallas–Fort Worth?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Dallas–Fort Worth to take part?
- Not necessarily. These studies have a site near Dallas–Fort Worth, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced cancer studies open near Dallas–Fort Worth regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.